Extended treatment-free hospitalization-free time and quality of life benefits with CAR T-cell therapy in subgroups of patients with relapsed/refractory MM: Insights from the KarMMa-3 trial

Category Primary study
Conference67th American Society of Hematology Annual Meeting, ASH 2025
Year 2025
This article has no abstract
Epistemonikos ID: 64592cebb64d608c1cb2113916680e5849852693
First added on: Jun 15, 2026